JPMorgan's survey reveals low coverage of weight-loss drugs compared to diabetes medications among large employers. The demand for these drugs poses challenges due to costs, with only a portion of companies planning to expand coverage in the future.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing